

Patent  
Attorney Docket No. 1034123-000170

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of  
Joseph L. Witztum et al.

Application No.: 10/552,330

Filing Date: October 11, 2005

Title: METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS

Group Art Unit: Unknown  
Examiner: Unknown  
Confirmation No.: Unknown

**FIRST  
INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL LLP

By

Michael P. Reed

Registration No. 45,647

Date: January 17, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Date of Deposit: January 17, 2006

Kim A. Cabello  
Typed Name:

(8/05)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of ) **MAIL STOP: IDS**  
Witztum et al. )  
 ) Group Art Unit: Unknown  
 )  
Application No.: 10/552,330 )  
 ) Examiner: Unknown  
 )  
Filed: October 11, 2005 )  
 ) Confirmation No.: Unknown  
 )  
For: METHODS AND COMPOSITIONS FOR )  
TREATING ATHEROSCLEROSIS )  
 ) Certificate of Mailing  
 ) I hereby certify that this correspondence is being  
 ) deposited with the United States Postal Service as first  
 ) class mail on January 17, 2006, in an envelope  
 ) addressed to the Commissioner for Patents, P.O. Box  
 ) 1450, Alexandria, VA 22313-1450  
 )  
 )  
 )  
 )  
By:   
Kim A. Cabello

**FIRST INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date January 17, 2006  
By:   
Michael P. Reed  
Registration No. 45,647

12230 El Camino Real  
Suite 300  
San Diego, CA 92130-2090  
(858) 509-7300

**FIRST  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Sheet 1 of 1

**Complete if Known**

**Application Number**

10/552,330

**Filing Date**

October 11, 2005

**First Named Inventor**

Joseph L. Witztum

**Examiner Name**

Unknown

## Shee

1 of

1

**Attorney Docket Number**

034123-000170

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Kearney, J. F., Immune Recognition of OxLDL in atherosclerosis, J. Clinical Investigation, June 2000, Vol. 105, No. 12, p. 1683-1685
	Shaw, P. X. et al., Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance and protective immunity, J. Clinical Investigation, June 2000, Vol. 105, No. 12, p. 1731 -1740

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.